Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans

Kidney International

Volumn 87, Issue 4, 2015, Pages 749-760

  Hosoya, Kozi ^a   Minakuchi, Hitoshi ^a   Wakino, Shu ^a   Fujimura, Keiko ^a   Hasegawa, Kazuhiro ^a   Komatsu, Motoaki ^a   Yoshifuji, Ayumi ^a   Futatsugi, Koji ^a   Shinozuka, Keisuke ^a   Washida, Naoki ^a   Kanda, Takeshi ^a   Tokuyama, Hirobumi ^a   Hayashi, Koichi ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

ADMA; Aldosterone; CKD; Insulin resistance; Mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; MINERALOCORTICOID RECEPTOR; N(G),N(G) DIMETHYLARGININE; PIG INSULIN; PLACEBO; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; AMIDASE; ARGININE; DIMETHYLARGININE; IMMEDIATE EARLY PROTEIN; MINERALOCORTICOID ANTAGONIST; PROTEIN SERINE THREONINE KINASE; RENIN; SERUM-GLUCOCORTICOID REGULATED KINASE;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOACCUMULATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL NUCLEUS; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; SPRAGUE DAWLEY RAT;

ADIPOSE TISSUE; AGED; ALDOSTERONE; AMIDOHYDROLASES; ANIMALS; ARGININE; CELL NUCLEUS; CYTOCHROME P-450 CYP11B2; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; IMMEDIATE-EARLY PROTEINS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NEPHRECTOMY; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN; SIGNAL TRANSDUCTION; SPIRONOLACTONE;

EID: 84926527017     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.348     Document Type: Article

References (60)

1. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
2. Feneberg R, Sparber M, Veldhuis JD et al. Altered temporal organization of plasma insulin oscillation in chronic renal failure. J Clin Endocrinol Metab 2002; 87: 1965-1973.
3. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
4. Banerjee D, Recio-Mayoral A, Chitalia N, Kaski JC. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients. Clin Cardiol 2011; 34: 360-365.
5. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone plasma lipoproteins, obesity and insulin resistance in Humans. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 401-405.
6. Catena C, Lapenna R, Baroselli S et al. Insulin sensitivity in patients with primary aldosteronesteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463.
7. Bia MJ, DeFronzo RA. Extrarenal potassium homeostasis. Am J Physiol 1981; 240: F257-F268.
8. Berle T, Katz FH, Henrich WL, DeTorrente A et al. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978; 14: 228-235.
9. Reubi FC, Weidmann P. Relationships between sodium clearance, plasma renin activity, plasma aldosterone, renal hemodynamics and blood pressure in essential hypertension. Clin Exp Hypertens 1980; 2: 593-612.
10. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. ADMA, cardiovascular disease and diabetes. Diabetes Res Clin Pract 2008; 82: S122-S126.
11. Yang ZC, Wang KS, Wu Y et al. Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: an effect prevented by vitamin E. Cell Physiol Biochem 2009; 24: 115-124.
12. Zoccali C, Bode-Bö ger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
13. Leiper JM, Santa Maria J, Chubb A et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209-214.
14. Okubo K, Hayashi K, Wakino S et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 2005; 28: 181-189.
15. Tatematsu S, Wakino S, Kanda T et al. Role of nitric oxide-producing and-degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2007; 18: 741-749.
16. Hasegawa K, Wakino S, Kimoto M et al. DDAH2 enhances pancreatic insulin secretion in mice via transcriptional regulation of secretagogin through Sirt1-dependent mechanism. FASEB J 2013; 27: 2301-2315.
17. Stü hlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426.
18. Hitomi H, Kiyomoto H, Nishiyama A et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007; 50: 750-755.
19. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376.
20. Briones AM, Nguyen Dinh Cat A, Callera GE et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59: 1069-1078.
21. Milagro FI, Campión J, Martínez JA. 11-Beta hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity. J Steroid Biochem Mol Biol 2007; 104: 81-84.
22. Tain YL, Kao YH, Hsieh CS et al. Melatonin blocks oxidative stress-induced increased asymmetric dimethylarginine. Free Radic Biol Med 2010; 49: 1088-1098.
23. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K et al. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009; 71: 1-6.
24. Costa MB, Andrade Ezequiel DG, Morais Lovis JC et al. Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2010; 12: 753-755.
25. Zulian E, Sartorato P, Benedini S et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 49-53.
26. Garg R, Kneen L, Williams GH, Adler GK. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab 2014; 16: 268-272.
27. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443.
28. Naito Y, Fujii A, Sawada H et al. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens 2012; 30: 2192-2201.
29. Shibata S, Mu S, Kawarazaki H et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptordependent pathway. J Clin Invest 2011; 121: 3233-3243.
30. Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1685-1691.
31. Wesson DE, Simon J. Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int 2010; 78: 1128-1135.
32. Hené RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
33. Williams GH, Bailey GL, Hampers CL et al. Studies on the metabolism of aldosterone on chronic renal failure and anephric man. Kidney Int 1973; 4: 280-288.
34. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000; 49: 1751-1760.
35. Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension 1992; 19: 26-29.
36. Wada T, Ohshima S, Fujisawa E et al. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 2009; 150: 1662-1669.
37. Kraus D, Jäger J, Meier B et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005; 37: 455-459.
38. Spoto B, Parlongo RM, Parlongo G et al. The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J Nephrol 2007; 20: 554-559.
39. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 2009; 53: 158-165.
40. Hirata A, Maeda N, Hiuge A et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-172.
41. Martínez-Ruiz A, Cadenas S, Lamas S. Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. Free Radic Biol Med 2011; 51: 17-29.
42. Doronzo G, Viretto M, Russo I et al. Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. Atherosclerosis 2011; 216: 44-53.
43. Mejá-Garcá TA, Portugal CC, Encarnação TG et al. Nitric oxide regulates AKT phosphorylation and nuclear translocation in cultured retinal cells. Cell Signal 2013; 25: 2424-2439.
44. Kubo M, Kiyohara Y, Kato I et al. Effect of hyperinsulinemia on renal function in a general population: Hisayama Study. Kidney Int 1999; 55: 2450-2456.
45. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
46. Pham H, Utzschneider KM, de Boer IH. Measurement of insulin resistance in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 640-646.
47. Lastra G, Dhuper S, Johnson MS, Sowers JR. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol 2010; 7: 577-584.
48. Tahara Y. Analysis of the method for conversion between levels of HbA1c and glycated albumin by linear regression analysis using a measurement error model. Diabetes Res Clin Pract 2009; 84: 224-229.
49. Freedman BI, Shihabi ZK, Andries L et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010; 31: 375-379.
50. Freedman BI, Andries L, Shihabi ZK et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1635-1643.
51. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
52. Chen J, Muntner P, Hamm LL et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477.
53. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care 2002; 25: 1177-1184.
54. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
55. Imai E, Horio M, Nitta K et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
56. Yamashita K, Okuyama M, Nakagawa R et al. Development of sensitive derivatization method for aldosterone in liquid chromatographyelectrospray ionization tandem mass spectrometry of corticosteroids. J Chromatogr 2008; 1200: 114-121.
57. Tsao PS, McEvoy LM, Drexler H et al. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89: 2176-2182.
58. Kaku K, Fiedorek FT Jr, Province M, Permutt MA. Genetic analysis of glucose tolerance in inbred mouse strains. Evidence for polygenic control. Diabetes 1988; 37: 707-713.
59. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-124.
60. Hasegawa K, Wakino S, Tanaka T et al. Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1488-1494.